Jordt Raymond M 4

What Happened Raymond M. Jordt, Altimmune's Chief Business Officer, acquired 4,571 shares on January 31, 2026 at an effective price of $3.07 per share, for a total value of $14,033. The Form 4 records the transaction as an acquisition (code A) resulting from participation in the issuer's Employee Stock Purchase Plan (ESPP). This was a purchase (employees’ discounted-plan buy), which investors often view as a modestly positive signal but is commonly part of routine compensation/benefit programs rather than a discretionary open-market buy.

Key Details

• Transaction date: 2026-01-31; Filing date with SEC: 2026-02-02 (Form 4, accession 0001960780-26-000008).
• Shares acquired: 4,571; Price per share: $3.07; Total value: $14,033.
• Shares owned after transaction: not specified in the provided filing data.
• Footnotes: (F1) Purchase through Altimmune's 2019 ESPP for the offering period Aug 1, 2025–Jan 31, 2026. (F2) Purchase price was based on 85% of the closing price on Aug 1, 2025.
• Transaction code: A = award/grant/other acquisition (ESPP purchase). No indication in the provided data that this was a late filing.

Context ESPP purchases are typically automatic payroll contributions converted to shares at a discounted price on set purchase dates; they are less informative about an insider’s discretionary view than open-market buys but do show ongoing participation in company benefit plans. The dollar amount here is modest (~$14k), so this should be viewed as routine employee-plan activity rather than a large insider investment.